These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Selective determination of alpha 2-plasmin inhibitor activity in plasma using chromogenic substrate. Matsuda T; Ogawara M; Miura R; Seki T; Matsumoto T; Teramura Y; Nakamura K Thromb Res; 1984 Feb; 33(4):379-88. PubMed ID: 6200949 [TBL] [Abstract][Full Text] [Related]
5. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. Wuillemin WA; Eldering E; Citarella F; de Ruig CP; ten Cate H; Hack CE J Biol Chem; 1996 May; 271(22):12913-8. PubMed ID: 8662679 [TBL] [Abstract][Full Text] [Related]
6. [Relationship between antiplasmin capacity and concentration of alpha 2-plasmin inhibitor, alpha 2-macroglobulin, alpha 1-antitrypsin, antithrombin III or C1-inactivator in plasma of patients with transient ischemic attacks (author's transl)]. Matsuda T; Seki T; Miura R; Ogawara M; Yokouchi M; Yamanouchi H Rinsho Byori; 1980 Mar; 28(3):261-4. PubMed ID: 6154815 [No Abstract] [Full Text] [Related]
8. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Schapira M; Scott CF; James A; Silver LD; Kueppers F; James HL; Colman RW Biochemistry; 1982 Feb; 21(3):567-72. PubMed ID: 6175341 [No Abstract] [Full Text] [Related]
9. Clearance of human factor XIa-inhibitor complexes in rats. Wuillemin WA; Bleeker WK; Agterberg J; Rigter G; ten Cate H; Hack CE Br J Haematol; 1996 Jun; 93(4):950-4. PubMed ID: 8703832 [TBL] [Abstract][Full Text] [Related]
10. The regulation of human factor XIIa by plasma proteinase inhibitors. Pixley RA; Schapira M; Colman RW J Biol Chem; 1985 Feb; 260(3):1723-9. PubMed ID: 2578463 [TBL] [Abstract][Full Text] [Related]
11. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein. Olson ST; Sheffer R; Francis AM Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967 [TBL] [Abstract][Full Text] [Related]
12. Inactivation of kallikrein in human plasma. van der Graaf F; Koedam JA; Bouma BN J Clin Invest; 1983 Jan; 71(1):149-58. PubMed ID: 6184384 [TBL] [Abstract][Full Text] [Related]
13. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. Schapira M; Scott CF; Colman RW J Clin Invest; 1982 Feb; 69(2):462-8. PubMed ID: 6173399 [TBL] [Abstract][Full Text] [Related]
14. Plasma kallikrein activation and inhibition during typhoid fever. Colman RW; Edelman R; Scott CF; Gilman RH J Clin Invest; 1978 Feb; 61(2):287-96. PubMed ID: 74379 [TBL] [Abstract][Full Text] [Related]
15. Blood levels of proteinase inhibitors in pregnancy. Walker JE; Campbell DM; Ogston D Br J Obstet Gynaecol; 1982 Mar; 89(3):208-10. PubMed ID: 6175337 [TBL] [Abstract][Full Text] [Related]
16. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma. Gallimore MJ; Friberger P Thromb Res; 1982 Feb; 25(3):293-8. PubMed ID: 6917564 [No Abstract] [Full Text] [Related]
17. C1 inhibitor: the main inhibitor of human plasma kallikrein. Trumpi-Kalshoven MM; Kluft C Adv Biosci; 1978 Jul; 17():93-101. PubMed ID: 90628 [No Abstract] [Full Text] [Related]
18. Plasma coagulation proteases, proteolytic inhibitors, and their interaction with platelets. Rao AK; Schmaier AH; Colman RW Pathobiol Annu; 1982; 12():35-64. PubMed ID: 6186978 [No Abstract] [Full Text] [Related]
19. The fibrinolytic system in man. Reiner AP; Bell WR Crit Rev Oncol Hematol; 1984; 2(1):33-81. PubMed ID: 6085039 [TBL] [Abstract][Full Text] [Related]
20. C1 inhibitor: the predominant inhibitor of plasma kallikrein. Schapira M; de Agostini A; Colman RW Methods Enzymol; 1988; 163():179-85. PubMed ID: 3237074 [No Abstract] [Full Text] [Related] [Next] [New Search]